Study to assess the plasma concentration of tolebrutinib given as a tablet to adult participants with renal impairment compared to healthy participants.

Trial Identifier: POP16399
Sponsor: Sanofi
Start Date: March 2022
Primary Completion Date: August 2022
Study Completion Date: August 2022
Condition: Kidney Diseases

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description

Trial Locations

Country Location
GERMANY KIEL, GERMANY, 24105
UNITED STATES, Florida Miami, Florida, UNITED STATES, 33014
UNITED STATES, Minnesota St. Paul, Minnesota, UNITED STATES, 55114
UNITED STATES, Tennessee Knoxville, Tennessee, UNITED STATES, 37920